Table 1 The adverse effects and relative frequencies of different BTKi in B-cell malignancies
From: Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect
BTK inhibitors | Disease state | Adverse Effects | ||||||
|---|---|---|---|---|---|---|---|---|
Infection (grade ≥ 3)/pneumonia | Neutropenia | Diarrhea | Hypertension | Hemorrhagea/Major bleeding | Atrial fibrillation and flutter | References | ||
Ibrutinib | R/R CLL | Grade ≥ 3 11%/19% | 16% | 55% | 22% | 44%/1% | 3% | |
TN CLL | Grade ≥ 3 48%/4% | 4% | 68% | 22% | major bleeding 4% | 6% | ||
R/R MCL | Pneumonia 13% | 17% |  < 5% | 5% | Grade ≥ 3 6% | Grade ≥ 3 7% | [118] | |
WM | Pneumonia 12% | 13% | 32% | 16% | hematuria 10% | 15% | [119] | |
Zanubrutinib | B-cell malignancies (33%WM, 29%CLL/SLL, 19%MCL) | Grade ≥ 3 27%/21% | 36% | 23% | 12% | 55% / 4% | 3% | [120] |
Acalabrutinib | B-cell malignancies | Grade ≥ 3 (18%)/9% | 12% | 37% | 8% | 4% | 4% | [121] |
orelabrutinib | B-cell malignancies | Grade ≥ 3 (15%)/2% | 29% | 7% | – |  < 1% |  < 1% | [122] |
Pirtobrutinib | R/R B-cell malignancies | 7% | 13% | 17% | – |  < 5% |  < 1% (unrelate to pirtobrutinib) | [123] |
Fenebrutinib | R/R B-cell malignancies | Grade ≥ 3 (17%)/4% | 4% | 29% | – | 8% | – | [124] |
Vecabrutinib | R/R B-cell malignancies | – | 25% | – | – | – | – | [125] |